Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans

British Journal of Pharmacology
Clara ScioratiEmilio Clementi


Current therapies for muscular dystrophy are based on corticosteroids. Significant side effects associated with these therapies have prompted several studies aimed at identifying possible alternative strategies. As inflammation and defects of nitric oxide (NO) generation are key pathogenic events in muscular dystrophies, we have studied the effects of combining the NO donor isosorbide dinitrate (ISDN) and the non-steroidal anti-inflammatory drug ibuprofen. alpha-Sarcoglycan-null mice were treated for up to 8 months with ISDN (30 plus ibuprofen (50 administered daily in the diet. Effects of ISDN and ibuprofen alone were assessed in parallel. Drug effects on animal motility and muscle function, muscle damage, inflammatory infiltrates and cytokine levels, as well as muscle regeneration including assessment of endogenous stem cell pool, were measured at selected time points. Combination of ibuprofen and ISDN stimulated regeneration capacity, of myogenic precursor cells, reduced muscle necrotic damage and inflammation. Muscle function in terms of free voluntary movement and resistance to exercise was maintained throughout the time window analysed. The effects of ISDN and ibuprofen administered separately were t...Continue Reading

Associated Clinical Trials

Nov 16, 2020·Paolo Manunta


May 1, 1981·Muscle & Nerve·M Ontell
Sep 23, 1998·The Journal of Cell Biology·F DuclosK P Campbell
Dec 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·D S Bredt
Nov 11, 1999·Cell Death and Differentiation·L Liu, J S Stamler
Nov 4, 2000·Expert Opinion on Investigational Drugs·H P DeignerR Kinscherf
Jan 12, 2001·Physiological Reviews·J S Stamler, G Meissner
Aug 30, 2001·Neuromuscular Disorders : NMD·M J Spencer, J G Tidball
Oct 3, 2001·The Journal of Cell Biology·M WehlingJ G Tidball
Oct 27, 2001·British Journal of Clinical Pharmacology·J LötschG Geisslinger
Mar 7, 2002·Lancet·Alan E H Emery
Oct 29, 2002·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Henry FarrarMichael Gill
Feb 8, 2003·Science·Enzo NisoliMichele O Carruba
Feb 18, 2003·Journal of Anatomy·Margaret BuckinghamFrédéric Relaix
Oct 16, 2003·Trends in Pharmacological Sciences·Emilio ClementiJacopo Meldolesi
Oct 24, 2003·Apoptosis : an International Journal on Programmed Cell Death·S S Jejurikar, W M Kuzon
Apr 1, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Miranda D Grounds, Jo Torrisi
Apr 24, 2004·The Cochrane Database of Systematic Reviews·A Y ManzurA Swan
Sep 17, 2004·Muscle & Nerve·Christopher L MendiasRonald E Allen
Oct 7, 2004·Trends in Molecular Medicine·Giulio Cossu, Maurilio Sampaolesi
May 26, 2005·Pharmacological Reviews·Vincenzo MollaceDaniela Salvemini
Jun 1, 2005·Neuroscience Letters·Maria Julia MarquesHumberto Santo Neto
Aug 24, 2005·Muscle & Nerve·Elisabeth R BartonThierry Toursel
Sep 3, 2005·Neurobiology of Disease·Vincent VoisinSabine De la Porte
Sep 6, 2005·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Xiuli ZhaoDanlei Wang
Nov 19, 2005·Expert Review of Cardiovascular Therapy·Keith C Ferdinand
Feb 9, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jonathan D ArcherJudy E Anderson
Dec 13, 2006·Expert Opinion on Investigational Drugs·Silvia BrunelliEmilio Clementi
Dec 22, 2006·Proceedings of the National Academy of Sciences of the United States of America·Silvia BrunelliEmilio Clementi
Mar 9, 2007·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·S LeroyG Pons
Apr 28, 2007·Journal of Applied Physiology·Abigail L MackeyHenning Langberg
Nov 16, 2007·Muscle & Nerve·Jenna L BettersDavid S Criswell
Jan 22, 2008·Neuromuscular Disorders : NMD·Hannah G RadleyMiranda D Grounds
Oct 15, 2008·PloS One·Justin M PercivalStanley C Froehner
Oct 28, 2008·Nature·Yvonne M KobayashiKevin P Campbell
Nov 21, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Kathryn R Wagner
Dec 3, 2008·Proceedings of the National Academy of Sciences of the United States of America·Claudia ColussiCarlo Gaetano

❮ Previous
Next ❯


Nov 16, 2012·Cell Death & Disease·C De PalmaE Clementi
Nov 26, 2013·European Journal of Pharmacology·Patrizia Rovere-QueriniSilvia Brunelli
Jul 24, 2012·Molecular Neurobiology·Clara De Palma, Emilio Clementi
Sep 7, 2014·The Journal of Physiology·James G Tidball, Michelle Wehling-Henricks
Feb 7, 2012·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Maria Grazia D'AngeloEmilio Clementi
Oct 13, 2011·The Journal of Pathology·Virginie Carmignac, Madeleine Durbeej
Oct 9, 2012·Muscle & Nerve·Giuseppe D'AntonaRoberto Bottinelli
Aug 25, 2015·Orphanet Journal of Rare Diseases·Daniela MigliettaEmilio Clementi
Apr 10, 2015·Cellular and Molecular Life Sciences : CMLS·Clara ScioratiPatrizia Rovere-Querini
May 26, 2011·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Clara ScioratiEmilio Clementi
May 7, 2013·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Clara ScioratiRoberto Latini
Dec 30, 2017·The Journal of Pharmacology and Experimental Therapeutics·Alyssa F CollierRobert J Bloch
Jul 3, 2015·American Journal of Physiology. Cell Physiology·Deanna GigliottiJudy E Anderson
Jan 22, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Elena RigamontiPatrizia Rovere-Querini
Dec 3, 2016·Journal of Neuromuscular Diseases·Hala S Alameddine, Jennifer E Morgan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.